Immediate Impact

65 standout
Sub-graph 1 of 23

Citing Papers

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
2 intermediate papers

Works of Luwen Mu being referenced

Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
2020
Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results
2017
and 1 more

Author Peers

Author Last Decade Papers Cites
Luwen Mu 385 221 163 23 629
Akhil Chopra 331 342 78 27 723
Guoliang Shao 365 148 85 32 527
Chang‐Jun Tan 329 177 165 27 689
Bowen Zhu 338 167 66 21 563
Francesca Benevento 293 138 92 19 685
Vikki Tang 555 181 195 18 694
Linjing An 379 128 96 19 586
Oxana V. Makarova‐Rusher 266 327 105 17 695
Yong‐Fa Zhang 379 156 168 31 629
Donald Poon 242 222 103 19 681

All Works

Loading papers...

Rankless by CCL
2026